A perspective is offered on the recent development of Src-homology 2 (SH2)
antagonists of Src, Grb2 and ZAP-70. Inhibiting Src SH2 is believed to be a
potentially attractive way of regulating bone resorption, Grb2 SH2 has bee
n shown to be an important component of the mitogenic ras pathway; and thus
might be of utility in cancer research. ZAP-70 is a tyrosine kinase that i
s expressed solely in T-cells and natural killer cells. Since inhibition of
the tandem SH2 domains of ZAP-70 has been shown to block T-cell proliferat
ion, antagonists for this particular protein could have implications in imm
une suppression. The emphasis of the article is placed on the structure-bas
ed design, synthesis and biological activity of a number of newly reported
SH2 antagonists in each of the three areas.